Diabetic Gastroparesis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Online Pharmacies is the fastest growing sector, North America is the largest market

The global market for diabetic gastroparesis treatments is projected to expand from USD 3.03 Billion in 2025 to USD 3.74 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 3.57%. This market includes pharmacological interventions like prokinetics and antiemetics, alongside surgical devices and procedures, all aimed at managing delayed gastric emptying in diabetic patients. A key driver for this growth is the increasing worldwide prevalence of diabetes, which in turn leads to a higher occurrence of gastrointestinal issues requiring effective symptom management. For example, in 2024, the International Diabetes Federation reported that approximately 589 million adults globally were living with diabetes, forming a large patient demographic prone to such long-term complications.

However, the market's growth faces a notable obstacle due to the rigorous regulatory environment governing drug safety and efficacy. Many current treatments are associated with severe adverse effects, compelling regulatory bodies to enforce stringent clinical trial standards and issue safety warnings for both new and existing medications. This strict oversight creates a significant barrier to market entry, extending product development timelines and limiting the approval of innovative therapeutic agents, consequently narrowing the range of treatment options available to healthcare providers and patients.

Market Drivers

A significant driver for the market's advancement is the strong clinical pipeline and the ongoing development of novel therapeutics, as pharmaceutical companies strive to create safer alternatives to conventional prokinetic agents. Manufacturers are focusing on formulating new chemical entities to reduce cardiac and neurological risks linked to older medications like metoclopramide, thereby addressing persistent regulatory safety issues. A notable example of this progress is CinDome Pharma's May 2024 announcement of securing a $40 million Series B financing extension to progress Phase 2 clinical trials for deudomperidone, an innovative dopamine antagonist designed to offer chronic symptom relief without the side effects of current treatments. This substantial investment in development underscores the industry's dedication to expediting the launch of advanced pharmacological solutions for gastroparesis management.

Concurrently, the rising global prevalence of diabetes mellitus is a foundational element driving the demand for gastroparesis treatments, establishing a large and expanding target patient demographic. As diabetes diagnoses increase, the incidence of associated gastrointestinal complications also rises proportionally, mandating ongoing therapeutic interventions to manage delayed gastric emptying. For instance, in May 2024, the Centers for Disease Control and Prevention reported that about 38.4 million people of all ages in the United States were living with diabetes, highlighting the vast number of at-risk individuals in key markets. This growing patient base directly translates into higher commercial adoption of approved therapies; for example, Evoke Pharma stated in November 2024 that net product sales for its nasal formulation, GIMOTI, reached $2.7 million in the third quarter, marking a 70% increase year-over-year.

Market Challenges

The rigorous regulatory environment surrounding drug safety and efficacy presents a substantial impediment to the expansion of the Global Diabetic Gastroparesis Treatment Market. Regulatory authorities mandate stringent clinical trial standards to reduce severe risks, particularly those linked to the prolonged use of current prokinetic agents. This demanding requirement for safety data necessitates lengthy and expensive development phases, frequently resulting in product failures during late-stage trials. As a result, the hesitance to approve new agents without conclusive safety evidence establishes a barrier to entry that curtails innovation and restricts the introduction of novel therapies, forcing the market to depend on older medications with inherent risks.

This regulatory constraint consequently limits the market's commercial potential by reducing the array of available treatments for a well-defined patient population experiencing significant suffering. The discrepancy between the considerable burden of the disease and the scarcity of approved therapeutic alternatives is evident in recent prevalence figures. The American Gastroenterological Association reported that in 2025, gastroparesis affected approximately 21 to 24 per 100,000 individuals in the United States, with women constituting the majority of cases. This statistic underscores a significant addressable market that continues to be underserved due to the slow rate of regulatory approvals, thereby directly hindering revenue generation and overall market growth.

Market Trends

A notable trend is the growing adoption of Gastric Peroral Endoscopic Myotomy (GPOEM), signifying a fundamental shift towards minimally invasive interventions for cases of gastroparesis that are resistant to other treatments. This procedure works by mechanically addressing pyloric spasms to improve gastric emptying, providing an alternative for patients who do not respond to pharmacological management. Medical professionals are increasingly employing GPOEM due to its potential to offer more lasting symptom relief compared to conventional surgical approaches. As published in Gastrointestinal Endoscopy in January 2025, a meta-analysis of 982 patients, detailed in the study 'Efficacy and safety of gastric peroral endoscopic myotomy across different etiologies of gastroparesis,' reported a pooled clinical success rate of 65% specifically for diabetes-related gastroparesis.

Concurrently, the market is expanding through the broader application of Gastric Electrical Stimulation for refractory cases, reaching patient groups previously not considered for device-based therapies. This trend involves exploring neurostimulation for individuals experiencing chronic nausea and vomiting who nonetheless have normal gastric emptying rates. Manufacturers are prioritizing clinical trials to confirm this expanded indication. For example, Enterra Medical announced in June 2025, via their press release 'New Hope for Chronic Nausea, Enterra Medical Begins NAVIGATE Study,' the commencement of a pivotal trial enrolling a minimum of 148 subjects to evaluate the safety and effectiveness of this approach within this growing patient population.

Key Market Players

• ANI Pharmaceuticals, Inc.
• Evoke Pharma
• Janssen Pharmaceutica N.V
• Teva Pharmaceuticals Inc.
• Pfizer Inc.
• Salix Pharmaceuticals, Inc.
• Allergan Plc.
• Novartis AG
• SCHWITZ BIOTECH
• Wellona Pharmaceutical Private Limited

Report Scope

In this report, the Global Diabetic Gastroparesis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Gastroparesis Treatment Market, by Type:

• Grade 2(Compensated Gastroparesis)
• Grade 3(Gastric Failure)

Diabetic Gastroparesis Treatment Market, by Drug Class:

• Gastroprokinetic Agents
• Antiemetic Agents
• Antihistamines
• Others

Diabetic Gastroparesis Treatment Market, by Route of Administration:

• Oral
• Parenteral
• Nasal

Diabetic Gastroparesis Treatment Market, by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Diabetic Gastroparesis Treatment Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Gastroparesis Treatment Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.